Antigens: Substances that are recognized by the immune system and induce an immune reaction.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.Antigens, Polyomavirus Transforming: Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Antigens, Fungal: Substances of fungal origin that have antigenic activity.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Antigens, Helminth: Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.H-2 Antigens: The major group of transplantation antigens in the mouse.Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.Antigens, Viral, Tumor: Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.Receptors, Antigen, T-Cell: Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.HLA-DR Antigens: A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Histocompatibility Antigens: A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.Histocompatibility Antigens Class II: Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.Receptors, Antigen, B-Cell: IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.Antigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.Epitopes: Sites on an antigen that interact with specific antibodies.Prostate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.O Antigens: The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)Antigens, CD15: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.HLA-A2 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Antigens, CD8: Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.Ca(2+) Mg(2+)-ATPaseEnzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Antigens, CD3: Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Blood Group Antigens: Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.Hepatitis B Surface Antigens: Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Cell Line: Established cell cultures that have the potential to propagate indefinitely.HLA-A Antigens: Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.Mice, Inbred BALB CAmino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Histocompatibility Antigens Class I: Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.HLA-D Antigens: Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Receptors, Antigen: Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.CA1 Region, Hippocampal: One of four subsections of the hippocampus described by Lorente de No, located furthest from the DENTATE GYRUS.Fluorescent Antibody Technique: Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.Antigens, CD45: High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.Hepatitis B Antigens: Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.Antigens, CD4: 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.CA3 Region, Hippocampal: A subsection of the hippocampus, described by Lorente de No, that is located between the HIPPOCAMPUS CA2 FIELD and the DENTATE GYRUS.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.Antigens, CD1: Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Antigens, Differentiation: Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.HLA-B Antigens: Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Calcium-Transporting ATPases: Cation-transporting proteins that utilize the energy of ATP hydrolysis for the transport of CALCIUM. They differ from CALCIUM CHANNELS which allow calcium to pass through a membrane without the use of energy.Mice, Inbred C57BLMART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.HIV Antigens: Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.Antigens, CD80: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Epstein-Barr Virus Nuclear Antigens: Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.Antigens, CD19: Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.Molecular Weight: The sum of the weight of all the atoms in a molecule.Sarcoplasmic Reticulum: A network of tubules and sacs in the cytoplasm of SKELETAL MUSCLE FIBERS that assist with muscle contraction and relaxation by releasing and storing calcium ions.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).CA-19-9 Antigen: Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Antigens, Heterophile: Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.Spleen: An encapsulated lymphatic organ through which venous blood filters.Hepatitis B Core Antigens: The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.Antigens, CD40: A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.Autoantigens: Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Antigens, Thy-1: A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.CA-125 Antigen: Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits CA(2+)-TRANSPORTING ATPASE mediated uptake of CALCIUM into SARCOPLASMIC RETICULUM.Cell Membrane: The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.Forssman Antigen: A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.H-Y Antigen: A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.Antigen-Presenting Cells: A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.Dendritic Cells: Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.Complement Fixation Tests: Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.HLA-DQ Antigens: A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.Antigens, CD86: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Simian virus 40: A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Electrophoresis, Polyacrylamide Gel: Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.Calcium Channel Blockers: A class of drugs that act by selective inhibition of calcium influx through cellular membranes.Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.Receptors, Antigen, T-Cell, alpha-beta: T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Peptides: Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Immunoelectrophoresis: A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.Immunity, Cellular: Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.Sodium-Calcium Exchanger: An electrogenic ion exchange protein that maintains a steady level of calcium by removing an amount of calcium equal to that which enters the cells. It is widely distributed in most excitable membranes, including the brain and heart.CTLA-4 Antigen: An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Caffeine: A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling.Guinea Pigs: A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.Calcium Channels, L-Type: Long-lasting voltage-gated CALCIUM CHANNELS found in both excitable and nonexcitable tissue. They are responsible for normal myocardial and vascular smooth muscle contractility. Five subunits (alpha-1, alpha-2, beta, gamma, and delta) make up the L-type channel. The alpha-1 subunit is the binding site for calcium-based antagonists. Dihydropyridine-based calcium antagonists are used as markers for these binding sites.Antigens, CD79: A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Cytosol: Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Hemagglutination Tests: Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Patch-Clamp Techniques: An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.gp100 Melanoma Antigen: A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.Serologic Tests: Diagnostic procedures involving immunoglobulin reactions.Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.Lewis Blood-Group System: A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.Antigens, CD2: Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.Antibodies, Helminth: Immunoglobulins produced in a response to HELMINTH ANTIGENS.Cloning, Molecular: The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.Antigens, T-Independent: Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.Immune Tolerance: The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.Cytotoxicity, Immunologic: The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Hepatitis B e Antigens: A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.Antigens, CD95: A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.Clone Cells: A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)Antigens, CD28: Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Hypersensitivity, Delayed: An increased reactivity to specific antigens mediated not by antibodies but by cells.Membrane Proteins: Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.Antigens, Nuclear: Immunologically detectable substances found in the CELL NUCLEUS.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Immunoassay: A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.Immunoblotting: Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.Minor Histocompatibility Antigens: Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.Recombinant Fusion Proteins: Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.Hybridomas: Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.Major Histocompatibility Complex: The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.HLA-B27 Antigen: A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Hepatitis delta Antigens: Antigens produced by various strains of HEPATITIS D VIRUS.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.HLA-C Antigens: Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).Antigens, CD58: Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.Fluorescent Dyes: Agents that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags.Ryanodine Receptor Calcium Release Channel: A tetrameric calcium release channel in the SARCOPLASMIC RETICULUM membrane of SMOOTH MUSCLE CELLS, acting oppositely to SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES. It is important in skeletal and cardiac excitation-contraction coupling and studied by using RYANODINE. Abnormalities are implicated in CARDIAC ARRHYTHMIAS and MUSCULAR DISEASES.Antigens, CD1d: A major histocompatibily complex class I-like protein that plays a unique role in the presentation of lipid ANTIGENS to NATURAL KILLER T-CELLS.Chelating Agents: Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.HLA-A1 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*01 allele family.Polysaccharides, Bacterial: Polysaccharides found in bacteria and in capsules thereof.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Inositol 1,4,5-Trisphosphate Receptors: Intracellular receptors that bind to INOSITOL 1,4,5-TRISPHOSPHATE and play an important role in its intracellular signaling. Inositol 1,4,5-trisphosphate receptors are calcium channels that release CALCIUM in response to increased levels of inositol 1,4,5-trisphosphate in the CYTOPLASM.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.HLA-B7 Antigen: A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*07 allele family.Species Specificity: The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.HLA-DR4 Antigen: An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*04 alleles.Calmodulin: A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Calcium-Binding Proteins: Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS.ABO Blood-Group System: The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.HLA-DR3 Antigen: An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*03 alleles.Agglutination Tests: Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed)Erythrocytes: Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Bacterial Proteins: Proteins found in any species of bacterium.Antigens, CD5: Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Kinetics: The rate dynamics in chemical or physical systems.Antigens, CD20: Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Binding Sites, Antibody: Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.Isoantigens: Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.Antigens, CD27: A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.HLA-A24 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*24 allele family.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Dose-Response Relationship, Immunologic: A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.Radioimmunoassay: Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.Adenosine Triphosphate: An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.

Paracrine changes in the peritoneal environment of women with endometriosis. (1/616)

During the past decade, macrophage-derived substances such as prostanoids, cytokines, growth factors and angiogenic factors have been detected in the peritoneal fluid of women with endometriosis. In particular, growth-promoting and angiogenic factors are considered to be substantially involved in the pathogenesis of endometriosis. In this study, vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-beta) and intercellular adhesion molecule 1 (ICAM-1), substances recently detected in the peritoneal fluid of women with endometriosis, were assessed with regard to their concentrations in different stages of endometriosis and changes of the peritoneal paracrine activity after medical treatment with a gonadotrophin releasing hormone agonist (GnRHa). Peritoneal fluid was obtained from patients with endometriosis during laparoscopy before and after a 4-month treatment with a GnRHa. VEGF, TGF-beta and ICAM-1 could be detected in all women presenting with various stages of active endometriosis. After GnRHa therapy, all patients showed significant decreases in mean concentrations of VEGF (194+/-77 pg/ml), TGF-beta (902+/-273 pg/ml) and ICAM-1 (157+/-52 ng/ml). Patients with stage III and IV endometriosis (according to the rAFS score) had much higher concentrations of VEGF and TGF-beta before treatment compared with those patients with mild endometriosis (rAFS stages I and II). The most striking decrease in concentration was for TGF-beta, from 902 pg/ml before to 273 pg/ml after therapy. These results indicate an important role for paracrine activity in the establishment and maintenance of endometriosis. Indeed, treatment with a GnRHa may reduce paracrine activity in the peritoneal cavity via hypo-oestrogenism and provide proof of successful therapy.  (+info)

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. (2/616)

PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel. PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived from four different trials and 625 patients treated with platinum from two trials were analyzed using precisely defined 50% and 75% reductions in CA-125. The standard and CA-125 response rates to paclitaxel and platinum were compared. In addition, we analyzed individual patient groups in which there was a difference in response according to the two response criteria. RESULTS: Patients with stable disease as determined by standard criteria who were treated with platinum and responded according to CA-125 criteria have an improved median progression-free survival compared with patients with stable disease who did not respond according to CA-125 criteria (10.6 v 4.8 months; P<.001). Standard and CA-125 response rates for patients treated with platinum (58.93% v 61.31%, respectively) and paclitaxel (30.65% v 31.67%, respectively) were very similar, as were rates of false-positive prediction of response by CA-125 (platinum 2.2% and paclitaxel 2.9%). Responders to paclitaxel had a significantly improved progression-free survival compared with non-responders by both standard criteria (median progression-free survival, 6.8 v 2.5 months; P<.001) and CA-125 criteria (median progression-free survival, 6.8 v 3.4 months; P<.001). CONCLUSION: Forassessing activity of therapy for ovarian cancer, these data show that precise 50% or 75% CA-125 response criteria are as sensitive as standard response criteria. We propose that they may be used as a measure of response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer. Sensitivity is maintained whether patients are treated with platinum or paclitaxel.  (+info)

Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. (3/616)

The aim of this study was to investigate cycle dependent changes of serum CA 125 and CA 15-3 concentrations during spontaneous ovulatory cycles. Twenty apparently healthy women with spontaneous menstrual cycles attending our infertility clinic were included. Of these women, 18 had occluded tubes as a result of sterilization. Ovulation was confirmed by luteinizing hormone test and ultrasonography and, to exclude endometriosis, a laparoscopy was performed. Serum samples for CA 125, CA 15-3, 17 beta-oestradiol and progesterone determinations were taken every second day starting on the 2nd day of the cycle until the 7th day of the next cycle. After correction for inter-individual variation in serum concentrations, highest CA 125 concentrations were found during the menstruation. During the follicular and peri-ovulatory phase CA 125 serum concentrations were lowest. For CA 15-3, serum concentrations were not statistically different throughout the cycle. CA 125 and oestradiol concentrations were negatively correlated, CA 15-3 and oestradiol concentrations were positively correlated. Absolute serum concentrations of both CA 125 and CA 15-3 vary among females. Within the female, fluctuations of CA 125 are phase related. In the population studied most of the patients had tubal obstruction and high CA 125 serum concentrations during menstruation, which revokes the theory that the menstrual rise of CA 125 is due only to retrograde menstruation.  (+info)

Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. (4/616)

OBJECTIVE: The aim of this study was to generate and evaluate artificial neural network (ANN) models from simple clinical and ultrasound-derived criteria to predict whether or not an adnexal mass will have histological evidence of malignancy. DESIGN: The data were collected prospectively from 173 consecutive patients who were scheduled to undergo surgical investigations at the University Hospitals, Leuven, between August 1994 and August 1996. The outcome measure was the histological classification of excised tissues as malignant (including borderline) or benign. METHODS: Age, menopausal status and serum CA 125 levels and sonographic features of the adnexal mass were encoded as variables. The ANNs were trained on a randomly selected set of 116 patient records and tested on the remainder (n = 57). The performance of each model was evaluated using receiver operating characteristic (ROC) curves and compared with corresponding data from an established risk of malignancy index (RMI) and a logistic regression model. RESULTS: There were 124 benign masses, five of borderline malignancy and 44 invasive cancers (of which 29% were metastatic); 37% of patients with a malignant or borderline tumor had stage I disease. The best ANN gave an area under the ROC curve of 0.979 for the whole dataset, a sensitivity of 95.9% and specificity of 93.5%. The corresponding values for the RMI were 0.882, 67.3% and 91.1%, and for the logistic regression model 0.956, 95.9% and 85.5%, respectively. CONCLUSION: An ANN can be trained to provide clinically accurate information, on whether or not an adnexal mass is malignant, from the patient's menopausal status, serum CA 125 levels, and some simple ultrasonographic criteria.  (+info)

Combined inhibin and CA125 assays in the detection of ovarian cancer. (5/616)

BACKGROUND: The reproductive hormone inhibin has been used as a diagnostic marker of ovarian mucinous and granulosa cell cancers. The aims of this study were to develop a new inhibin immunofluorometric assay (alphaC IFMA) to replace an inhibin RIA as a diagnostic marker of these ovarian cancers and to assess whether the alphaC IFMA in combination with CA125, which detects serous cancers, leads to an improved biochemical diagnosis of all ovarian cancers. METHODS: Serum inhibin concentrations were determined in healthy postmenopausal women (n = 165) and women with ovarian cancers (n = 154), using an inhibin RIA and an alphaC IFMA, which detects inhibin forms containing the alphaC subunit as well as the free alphaC subunit. RESULTS: The alphaC IFMA gave a similar or better discrimination of mucinous (90% vs 71%) and granulosa cell (100% vs 100%) cancers compared with the inhibin RIA. Combination of CA125 and alphaC IFMA values by canonical variate analysis or by multiROC analysis showed that the percentage of all ovarian cancers detected was significantly increased compared with either CA125 or alphaC IFMA alone. CONCLUSIONS: The alphaC IFMA shows a similar or better specificity compared with the RIA, but with increased sensitivity. In combination with CA125, the alphaC IFMA provides an effective dual test for the detection of the majority (90%) of ovarian cancers.  (+info)

Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. (6/616)

OBJECTIVE: Several cytokines and proteins are excreted intraperitoneally during the course of peritonitis and stable states in continuous ambulatory peritoneal dialysis (CAPD) patients. Dialysate hyaluronan (HYA) is also regarded as a marker of peritoneal healing during bacterial peritonitis. We examined here, intraperitoneal HYA production in stable CAPD patients and compared the results to those of the peritoneal equilibration test (PET), the length of time on dialysis, and other marker proteins. DESIGN: We determined the concentration of HYA and other marker proteins in the 4-hour-dwell dialysate at 1-year intervals. SETTING: CAPD unit in Hitachi General Hospital. PATIENTS: The subjects were 46 stable CAPD patients who underwent 104 PETs. RESULTS: A correlation was found between the length of time on dialysis and the amount of HYA excretion in the 4-hr-dwell dialysate (r = 0.403, p < 0.001). A positive but weak correlation was found between the dialysate-to-plasma ratio of the creatinine concentration and dialysate HYA excretion (r = 0.229, p < 0.05). Seven patients were over the 90th percentile in both the concentration of HYA (>349.2 ng/mL) and the amount of HYA (>743.6 microg/4-hr dwell). Five patients exceeded 1000 microg of HYA excretion in the 4-hr-dwell dialysate, 4 of whom showed an abrupt increase of HYA excretion to more than 1000 microg/4-hr dwell, and discontinued CAPD within 6 months due to ultrafiltration failure. Two of these 4 patients were diagnosed with sclerosing encapsulating peritonitis at autopsy. CONCLUSION: Intraperitoneal HYA production increased with both higher permeable membrane and the length of time on CAPD. Monitoring of HYA in the peritoneal dialysate may be useful as a marker to assess functional and morphological changes in the peritoneum in long-term CAPD patients.  (+info)

Serum CA-125 values on the day of oocyte retrieval are not predictive of subsequent pregnancy with in-vitro fertilization. (7/616)

In the clinical management of in-vitro fertilization (IVF) patients it would be very useful to know, before the embryo transfer, whether or not there is a significant chance of pregnancy in that cycle. If low, it would be better to freeze the embryos and postpone the embryo transfer to a subsequent cycle. For this reason, a retrospective study was carried out to investigate the correlations between the serum CA-125 values before embryo transfer and the clinical outcome of that IVF cycle. Women aged <40 years undergoing a complete infertility evaluation including laparoscopy and receiving gonadotrophin-releasing hormone analogue (GnRHa) suppression followed by purified follicle stimulating hormone (FSH) for IVF-embryo transfer were entered into the study. Ninety-seven cycles qualified for evaluation (26 pregnant and 71 non-pregnant cycles). CA-125 concentrations on the day of oocyte retrieval were significantly lower in the pregnant versus non-pregnant cycles in both non-endometriosis and endometriosis patients. To evaluate the existence of a cut-off value of CA-125 which would allow the prediction of a possible pregnancy with sufficient specificity and sensitivity, a receiver operating characteristic curve analysis was performed. This analysis demonstrated the absence of any predictive value of the subsequent pregnancy for CA-125 concentrations. For this reason, and in contrast with previous findings, CA-125 determinations before the embryo transfer in IVF patients do not appear to be a useful tool for clinicians to use in predicting the outcome of IVF in any given cycle.  (+info)

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. (8/616)

We have previously shown that, in asymptomatic post-menopausal women, serum CA125 elevation is associated with a 36-fold increase in risk of ovarian cancer. This study was undertaken to assess the value of pelvic ultrasound for further stratification of ovarian cancer risk. Of 22,000 post-menopausal women, aged > or = 45 participating in an Ovarian Cancer Screening Trial, 741 with a CA125 > or = 30 U ml(-1) underwent pelvic ultrasonography. Twenty index cancers (primary invasive epithelial carcinomas of the ovary and fallopian tube) were diagnosed amongst these 741 women during a median follow-up of 6.8 years. Ultrasound results separated the women with CA125 elevation into two groups. Those with normal ovarian morphology had a cumulative risk (CR) of index cancer of 0.15% (95% confidence interval (CI) 0.02-1.12) which is similar to that of the entire population of 22,000 women (0.22%, 95% CI 0.18-0.30). In contrast, women with abnormal ovarian morphology had a CR of 24% (15-37) and a significantly increased relative risk (RR) of 327 (156-683). Ultrasound can effectively separate post-menopausal women with raised CA125 levels into those with normal scan findings who are not at increased risk of index cancer and those with abnormal findings who are at substantially increased risk of index cancer.  (+info)

Fasting Required: No Specimen: Blood Results: 1-2 Business Days Description: Cancer antigen (CA) 27.29 is used to monitor metastatic carcinoma of the...
Biological progression-free interval is defined as the interval from the date of the first administration of any study treatment to the date of the first documented serial elevation of the ovarian cancer mucin CA-125. More precisely, this is defined as the first documented increase in CA-125 levels as follows: (1) CA-125 greater than or equal to 2 times the upper level of normal (ULN) on 2 occasions at least 1 week apart (for participants with CA-125 within normal range pre-treatment) or (2) CA-125 greater than or equal to 2 times the ULN on 2 occasions at least 1 week apart (for participants with elevated CA-125 pre-treatment and initial normalization of CA-125 on-treatment) or (3) CA-125 greater than or equal to 2 times the nadir value, which is the lowest observed CA-125 value per participant on 2 occasions at least 1 week apart (for participants with elevated CA-125 pre-treatment which never normalized ...
Quality CA-12-5 ELISA kit from ELISA kits manufacturer and elisa kits supplier : CA-12-5 ELISA Assay, CA-12-5 ELISA test, CA-125 ELISA kit, CA-125 ELISA Assay, CA-19-9 ELISA kit, CA-15-3 ELISA kit. Our kits are FDA, CE and ISO certified.
Quality CA-12-5 ELISA kit from ELISA kits manufacturer and elisa kits supplier : CA-12-5 ELISA Assay, CA-12-5 ELISA test, CA-125 ELISA kit, CA-125 ELISA Assay, CA-19-9 ELISA kit, CA-15-3 ELISA kit. Our kits are FDA, CE and ISO certified.
Standard initial treatment of ovarian cancer patients includes both surgery and chemotherapy which in the vast majority of cases achieves the disappearance of ovarian cancer lesions. This status, called clinical remission which means having no evidence of cancer on CT scan or physical examination needs to be carefully follow up in order to confirm the maintenance of the remission status or to early detect if the cancer grows again and then start a new chemotherapy. At present, no approved therapies exist for the maintenance treatment of patients who achieved the clinical remission.. This trial aims to evaluate if the repeated vaccination with Abagovomab creates an immunoresponse which is able to fight the cancer cells thus keeping the remission status as long as possible and help patients live disease-free and longer.. Patients who achieve the remission status after chemotherapy will be screened for study participation and if they meet the criteria for inclusion they will start to receive a ...
Elevated CA-72-4 levels are primarily used in monitoring treatment and disease course in patients with gastric cancer. In 70% of relapse cases, CA-72-4 increases prior or concurrently with clinical diagnosis of the relapse. Diagnostic sensitivity of CA-72-4 for gastric cancer increases to 66% when combination of CA-72-4,CEA,CA-125 and CA 19-9 are used. Can be elevated in ovarian and colorectal cancer ...
Alan RIACH {UK/NZ?} (M: 1957 - ?) Evans RIADORE (M: ? - 1861 Aug 18) José Antonio RIAL GONZÁLEZ {VE} (M: 1911 Apr 21 - ?) Providencia RIANCHO ESCOBALES {PR} (F: 1901 Aug 10 - ?) Prof, Nicholas (Valentine) RIASANOVSKY {US} (M: 1923 Dec 21 - 2011 May 14) Russia And West In The Teaching Of The Slavophiles [n,1952] A History Of Russia [n,1963] Prof, Carles RIBA {ES} (M: 1893 Dec 23 - 1959 Jul 12) Primer Llibre DEstances (aka: Estances) [Ca-1919] Escolis, I Altres Articles [Ca-1921] Carles Riba [?-1923] Els Marges [Ca-1927] Sis Joans [Ca-1928] Resum De Literatura Llatina [Ca-1933] Tres Suites [Ca-1937] Per Comprendre, 1927-1935 [Ca-1937] Resum De Literatura Grega [Ca-1937] Elegies De Bierville [?-1942] Del Joc I Del Foc [Ca-1946] LIngenu Amor [Ca-1948] Llegendari Català [Ca-1950] Les Aventures DEn Perot Marrasqui [Fr-1950] Salvatge Cor [p,Ca-1952] Més Els Poemes [n,Sp-1957] Esbós De Tres Oratoris [Ca-1957] Harold Uriel RIBALOW {US} (M: 1919 Jul 1 - ?) Albert RIBAUCOUR (M: 1845 Nov 28 - 1893 ...
Cancer Antigen 125 (CA-125) is a tumor marker primarily used to monitor treatment of ovarian cancer and to detect whether cancer has come back after treatment is complete. Sometimes CA-125 may be ordered to help detect early ovarian cancer in women at high risk (e.g., BRCA mutation) or to help investigate a lump in a womans lower abdominal area (pelvic mass).
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Ho on what if ca 125 doesnt change after chemo: CA 125 is not recommended as a screening tool for ovarian cancer when used in risk-based stratification. Meaning, assuming that your mom or sister didnt get diagnosed with ovarian cancer. Normal for women with endometriosis to have elevated CA-125. It sounds like your doctor has done Ultrasound to evaluate ovaries as well. Your MD knows your history and risk, likely this CA-125 level is normal
Cancer Antigen 125 (human) ELISA Kit: Colorimetric Assay for Quantitative measurement of human CA-125 in serum, plasma, urine & cell culture supernatants. Detection Range: 0.6 U/ml - 400 U/ml. 100 assays.
ca 15 3 normal range breast cancer - 28 images - ppt tumor markers powerpoint presentation id 6610494, clinical and technical evaluation of acs br serum assay of, introduction of cancer markers laboratory services, human cancer antigen ca15 3 breast cancer calibrator, ppt tumor markers powerpoint presentation id 6610494
Some labs need routine testing. Others need routine and specialty testing. With models custom-tailored to the needs of each, labs get the solution that fits their needs. The Sysmex CA-620 System offers clotting testing methodology for laboratories that primarily perform routine tests; the Sysmex CA-660 System offers clotting, chromogenic*, and immunologic* testing for laboratories that require a broader test menu and perform specialty testing.. ...
n. a tumour marker that can be detected by a simple blood test and is particularly useful in the diagnosis of ovarian cancer and also for subsequently monitoring its response to treatment. In a patient being evaluated for a pelvic mass, a CA125 level greater than 65 is associated with malignancy in approximately 90% of cases (see risk of malignancy index). A number of benign conditions, including benign ovarian tumours, can also cause elevations of the CA125 level, as can cancers other than ovarian cancer, including malignancies of the endometrium, lung, breast, and gastrointestinal tract. ...
Health, ...HOUSTON Evaluating its change over time CA-125 the protein long-rec...The updated findings are published in Cancer ; preliminary data ...MD Anderson has a long history in the research of the important biomar... Over the last ten years theres been a lot of excitement over new ma...,CA-125,change,over,time,shows,promise,as,screening,tool,for,early,detection,of,ovarian,cancer,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
CHO-Anti-Human CA-125 F(ab) stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CA-125 F(ab) gene to allow expression of the F(ab). It is an example of a cell line transfected using our proprietary CBTGS gene screening and amplification system.
CHO-Anti-Human CA-125 scFv stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CA-125 scFv gene to allow expression of the scFv. It is an example of a cell line transfected using our proprietary CBTGS gene screening and amplification system.
Offered on Sysmex CA-660 System only The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details. ...
CA-125 is an important part of the workup for suspicious adnexal masses and for for following treated ovarian cancer. It is not a common marker in clinical use
Many of you EndoSisters may have heard, or are following, the use of the biomarker CA-125 as a possible indicator of the presence of Endometriosis (read more here). I had my annual pap smear appointment this week and figured Id ask my doc to see if theyd run blood tests with my usual annual bloodwork.…
The Sysmex® CA-1500 System, with optional cap-piercing, is ideal for mid-volume laboratories requiring an easy to use analyzer capable of running clotting, chromogenic, and immunologic assays simultaneously. The system features multiple dilution analysis (MDA) for detecting inhibitors during factor assay analysis and accurate sample identification. By offering true 15-parameter random access testing and walk-away capability, the system offers both efficiency and flexibility for your laboratory.. ...
Sysmex® CA-1500 brzo analizira veliki broj uzoraka sa visokim nivoom preciznosti. Kompaktan, potpuno automatizovan sistem izvodi koagulometrijske, hromogene i imunološke testove ...
- Oregovomab in Combination with Chemotherapy Improves Clinical Outcome in Ovarian Cancer Patients TSX Venture: QPT EDMONTON , Nov.
FOR IMMEDIATE RELEASE Contact: Frank G., Owner/Product Developer, M14.ca, T97.ca, AR-15.ca. Call/Text 250 888 9982 PRE-ORDER NOW FROM www.AR-15.ca FOR $229.95 + TAX/SHIPPING. LIMITED QUANTITY. CA-15 PRODUCTION COMPLETION APRIL 2017. ALL ITEMS SHIP APRIL 2017. http://www.ar-15.ca/images/CA-15/ca-15-final-render-SM.JPG ENGINEERING AND DESIGN CONSIDERATIONS OF THE NEW CA-15 ADJUSTABLE CANTILEVER SCOPE MOUNT FROM AR-15.CA SUMMARY
CA 19-9 is a protein that may be elevated with some cancers, especially pancreatic cancer. A CA 19-9 test may be used to monitor treatment for pancreatic cancer.
Oganessian, Yu. Ts.; Utyonkov, V. K.; Lobanov, Yu. V.; Abdullin, F. Sh.; Polyakov, A. N.; Shirokovsky, I. V.; Tsyganov, Yu. S.; Mezentsev, A. N.; Iliev, S.; Subbotin, V. G.; Sukhov, A. M.; Subotic, K.; Ivanov, O. V.; Voinov, A. N.; Zagrebaev, V. I.; Moody, K. J.; Wild, J. F.; Stoyer, N. J.; Stoyer, M. A.; Lougheed, R. W.
JSC Isotope is an enterprise of Rosatom State Corporation working in the markets of isotope products, radiation devices, medical and general purpose equipment.
Infusions Ive interacted with a variety of professionals, and have decided to do some form of a fourth round, in order to get my CA-125 number down lower than the last reading of 38. It will be tested again on Tuesday morning, with other labs, before I see my gyn-onc, Dr. Guntupalli, and have infusions.…
Shop 1990 Ford Bronco Fuel Pumps, Regulators, Sending Units parts and get Free Shipping on orders over $99 at Speedway Motors, the Racing and Rodding Specialists. 1990 Ford Bronco Fuel Pumps, Regulators, Sending Units parts in-stock with same-day shipping.
TY - JOUR. T1 - Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. AU - Lu, Renquan. AU - Sun, Xinghui. AU - Xiao, Ran. AU - Zhou, Lei. AU - Gao, Xiang. AU - Guo, Lin. PY - 2012/3/9. Y1 - 2012/3/9. N2 - Human epididymis protein 4 (HE4) is a novel and specific biomarker for epithelial ovarian cancer (EOC). We previously demonstrated that serum HE4 levels were significantly elevated in the majority of EOC patients but not in subjects with benign disease or healthy controls. However, the precise mechanism of HE4 protein function is unknown. In this study, we generated HE4-overexpressing SKOV3 cells and found that stably transduced cells promoted cell adhesion and migration. Knockdown of HE4 expression was achieved by stable transfection of SKOV3 cells with a construct encoding a short hairpin DNA directed against the HE4 gene. Correspondingly, the proliferation and spreading ability of HE4-expressed cells were inhibited by HE4 suppression. ...
Background: Early diagnosis of ovarian cancer is essential for long term disease control and mortality reduction.This has been achieved using tumor markers like cancer antigen 125 (CA-125) which is elevated in malignant as wellas non-malignant conditions. This dilemma led to efforts towards development of newer markers like serum humanepididymis secretory protein E4 (HE4). Present study aimed to evaluate role of HE4 in diagnosing ovarian cancersand comparing it with CA-125. Methods: Serum samples from 67 patients with ovarian cancer, 42 with benignovarian masses and 26 healthy controls were collected preoperatively and tested for serum HE4 levels and CA-125levels. Diagnostic performance of both tumor markers (HE4/CA-125) to diagnose malignancy in ovarian masses wascalculated and compared to each other. Results: Mean CA-125 and HE4 levels were significantly higher in patientswith ovarian cancer than in those with benign disease (p|0.001) or healthy controls (p| 0.001). Serum HE4 levelssignificantly
Ovarian cancer is a common malignancy of the female reproductive system. Tumor markers serve as tools in the diagnosis of the disease. The aim of the present study was to determine the diagnostic value of sera levels of carbohydrate antigen-125 (CA-125), human epididymis protein 4 (HE4) as well as the area under the curve of the receiver operating characteristic (ROC) and the risk of ovarian malignancy algorithm (ROMA) index in ovarian cancer. The sera were measured using an electrochemiluminescence immunoassay on 158 individuals (64 patients with ovarian cancer, 64 with ovarian benign tumor and 30 healthy individuals) between September 2013 and May 2015. The results showed that levels of HE4 and CA‑125 in the sera of the ovarian benign tumor group as well as their ROMA index were significantly higher (P,0.05) than those of the ovarian benign tumor and control groups, regardless of pre‑ or postmenopausal status. However, the level of CA‑125 was significantly higher (P,0.05) in the ovarian ...
OBJECTIVE: The Risk of Malignancy Index (RMI) is a simple scoring system to standardize and improve the preoperative evaluation of adnexal masses. Since 1990, three versions of the RMI have been validated in different clinical studies. Recently, a fourth version of the RMI (RMI-4) was introduced that includes tumor size as an additional parameter. The aim of this study was to validate the ability of RMI-4 to discriminate between non-invasive lesions and invasive malignant adnexal masses, and to compare its performance with RMI-3. STUDY DESIGN: Women scheduled for surgery for an adnexal mass between 2005 and 2009 in 11 hospitals were included. Ultrasonographic characteristics, menopausal status and serum CA 125 level were registered preoperatively, and combined into the RMI. The performances of RMI-3 and RMI-4 were assessed and statistically tested for differences. RESULTS: A total of 643 patients were included: 469 benign, 73 borderline and 101 malignant tumors. The RMI-3 had a sensitivity of ...
Metastatic Ovarian Cancer-Pipeline Review, H2 2015. Summary. Global Markets Directs, Metastatic Ovarian Cancer-Pipeline Review, H2 2015, provides an overview of the Metastatic Ovarian Cancers therapeutic pipeline.. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC ...
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. The present study examined serum tumor marker levels of carcinoembryonic antigen and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.Methods: In this cross-sectional study, we assessed metastatic breast cancer patients diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad University of Medical Sciences. The patients were selected by systematic randomization sampling. Demographic, clinical, pathological, and therapeutic data were collected from patients hospital records. Statistical analyses were performed by Statistical Package for the Social Sciences version 16.0 software.Results: A total of 298 eligible patients enrolled in the study.
Background: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC).. Methods: Preoperative serum samples of 419 women (140 healthy controls, 131 ovarian benign cysts, 34 endometriosis, and 114 EOC) were tested for CA125 and HE4 using fully automated methods (Abbott ARCHITECT) and validated cutoff values.. Results: For the discrimination of benign masses from EOC, in premenopausal women, the sensitivity and specificity were 92.3% and 59.4% for CA125, 84.6% and 94.2% for HE4, and 84.6% and 81.2% for ROMA, whereas in postmenopausal women, the sensitivity and specificity were 94.3% and 82.3% for CA125, 78.2% and 99.0% for HE4, and 93.1% and 84.4% for ROMA. In patients with EOC, elevated CA125, HE4, and ROMA levels were associated with advanced Federation of Gynaecologists and Obstetricians (FIGO) stage, suboptimally debulking, ascites, positive cytology, ...
BACKGROUND: There is no universal screening method for discrimination between benign and malignant adnexal masses yet. Various authors have tried tumor markers, imaging studies, cytology but no one yet is a definite method for screening of cancer ovary, for which a combined diagnostic modality has come to practice in form of RMI. With this background we conducted our study "Evaluation of risk malignancy index and its diagnostic value in patients with adnexal masses". METHODS: The aim of the study was to determine the effectiveness of risk of malignancy index (RMI-3) in preoperative discrimination between benign and malignant masses and also to reveal the most suitable cut off value ...
An Unusual Association of Lung and Ovarian Malignancy in a Young Nonsmoker Female: 10.4018/ijudh.2012100104: Lung cancer in a 25-year-old nonsmoker female is extremely rare. Ovarian malignancy in this age group is also infrequent and if occurs, is usually of germ
High levels of CA-125, the specific tumour marker for epithelial ovarian cancers are also found in inflammatory diseases of the pelvis. This case report of a 28 year-old woman with pathological CA-125 levels demonstrates the association between this finding and ascites caused by miliary tuberculosis. Tuberculostatic chemotherapy led to normalisation of the CA-125 levels within 8 weeks.
Serum levels of CA 15-3, an antigen expressed by human breast carcinoma cells, were measured in 58 ovarian cancer patients, 24 patients with benign ovarian tumor and 62 patients with benign gynecological conditions. Abnormally high serum CA 15-3 levels were found in 41 of 58 patients (71%) with ovarian cancer. The percentage of CA 15-3 positivity correlated with tumor stage. Elevated serum CA 15-3 levels were found in 5 of 24 patients (20%) with benign ovarian tumor. None of the patients with benign gynecological conditions had increased serum CA 15-3 levels. Serial measurements showed CA 15-3 concentrations to be correlated with the clinical behavior of disease in 21 of 25 patients (84%). CA 15-3 serum levels were also found to be correlated with findings on second look. These results suggest that CA 15-3 may represent a useful tumor marker in ovarian cancer.
Although some patients can be treated with surgery and chemotherapy, eventually most metastatic ovarian cancers become resistant to treatment. New options are needed for patients with advanced ovarian...
Thanks! ,From: Jim Kenzig http://thethin.net; ,[email protected], ,Reply-To: [email protected] ,To: ,[email protected],, ,[email protected], ,Subject: [THIN] FW: CERT Advisory CA-2003-09 Buffer Overflow in Microsoft ,IIS 5.0 ,Date: Mon, 17 Mar 2003 19:05:52 -0500 , , ,If you are running IIS 5 patch now or suffer later. ,JK , ,-----Original Message----- ,From: CERT Advisory [mailto:[email protected]] ,Sent: Monday, March 17, 2003 2:07 PM ,To: [email protected] ,Subject: CERT Advisory CA-2003-09 Buffer Overflow in Microsoft IIS 5.0 , , , , ,-----BEGIN PGP SIGNED MESSAGE----- , ,CERT Advisory CA-2003-09 Buffer Overflow in Microsoft IIS 5.0 , , Original issue date: March 17, 2003 , Last revised: -- , Source: CERT/CC , , A complete revision history is at the end of this file. , ,Systems Affected , , * Systems running Microsoft Windows 2000 with IIS 5.0 enabled , ,Overview , , A buffer overflow vulnerability exists in Microsoft IIS 5.0 running on , Microsoft Windows 2000. ...
Fred Hutchinson Cancer Center researchers discovered that concentrations of the serum biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only…
Cancer varies depending on the person, and this is also true when it comes to ovarian cancer. Learn more about what will come after diagnosis.
Researchers have developed a simple blood test that measures the bodys own immune response to improve diagnosis of ovarian cancer.
There are four stages of ovarian, fallopian tube, and peritoneal cancers. Learn how MSK doctors use this information to create a customized treatment plan.
When talking about my cancer diagnosis, Id say there are two parts to my story: The first part, when I fought for answers, and the second part,...
95% for ovarian malignancy. In patients who are not as carefully selected clinically, the utility of this test decreases, thus highlighting the need for careful clinical scrutiny. MUC16 (CA-125) has been shown to play a role in advancing tumorigenesis and tumor proliferation by several different mechanisms. One way that MUC16 helps the growth of tumors is by suppressing the response of natural killer cells, thereby protecting cancer cells from the immune response. Further evidence that MUC16 can protect tumor cells from the immune system is the discovery that the heavily glycosylated tandem repeat domain of MUC16 can bind to galectin-1 (an immunosuppressive protein). MUC16 is also thought to participate in cell-to-cell interactions that enable the metastasis of tumor cells. This is supported by evidence showing that MUC16 binds selectively to mesothelin, a glycoprotein normally expressed by the mesothelial cells of the peritoneum (the lining of the abdominal cavity). MUC16 and mesothelin ...
Ovarian cancer is a silent killer; however, improvements in identification of women at high risk for ovarian cancer, as well as improved imaging techniques, have increased the likelihood of early dete... more
... FEEDS AND CRIMPS REEL SMART™ CONTINUOUSLY MOLDED TERMINALS, DISCONNECTS AND SPLICES IN AUTOMATIC WIRE PROCESSING MACHINES AND BENCH PRESSES OPERATION MANUAL INTRODUCTION.................................................................. 1 SYSTEM SPECIFICATIONS ...................................................... 1 SAFETY PRACTICES............................................................. 1 WIRE PROCESSING MACHINE / PRESS COMPATIBILITY BY MANUFACTURER.................................... 2 APPLICATOR INSTALLATION PANDUIT CP-861 Bench Press .................................................. 3 APPLICATOR SETUP Die Insert Installation............................................................ Die Insert Changeover .......................................................... Crimp Shut Height Tolerance Test ............................................ REEL SMART™ System Reference Table ..................................... Applicator Loading ...
What is the best time to start with CA-98? CA-98 capsules are effective in the fight against the aging of the body, But what is the right time to start taking CA-98 capsules? For which age group are the capsules the most suitable? CA-98 capsules are suitable for everyone, but when is the best time to start? Before […]. ...
A young advocate emphasizes the importance of communication between parents and their children about an ovarian cancer diagnosis.
This glycoprotein is a mucinous carbohydrate antigen product of the MUC1 gene expressed on various adenocarcinomas, especially breast. It is a high molecular weight (300-450 kDa) 1 polymor... ...
Unauthorized use of any materials presented here is prohibited. Copying or reproducing any elements from this page is not permitted. All prices, descriptions and availability subject to change ...
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Device connector for front wall, straight, shielded: Yes, SPEEDCON locking, M23, No. of pos.: 7, type of contact: Pin, Crimp connection, Axial seal, Central fastening M20 x 1.5
SONERIE TROMPETA SYNCROMATE http://www.bikexpert.ro/userfiles/3f36334d-27dd-49ca-9d2d-ba2ff682895f/products/3488545_list.jpg Syncromate ...
EXTON, Pa., Dec. 7, 2015 /PRNewswire/ -- Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With...
article{9a867211-15c1-48ad-af36-1d7fbbbfc375, abstract = {,p,BACKGROUND/AIM: To assess preoperative blood levels of a biomarker panel in relation to the new classification system of epithelial ovarian cancer (EOC) type I and II.,/p,,p,PATIENTS AND METHODS: Preoperative plasma levels of B7-family protein homolog 4 (B7-H4), intact and cleaved soluble urokinase plasminogen activator receptor (suPAR), human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) were analyzed in 350 patients with adnexal lesions.,/p,,p,RESULTS: The levels of suPAR(II-III), HE4, CA125 were all higher in EOC II than in EOC I, borderline and benign ovarian tumors. B7-H4 was increased in EOC II compared with benign ovarian tumors. The combination of suPAR(II-III), HE4, CA125 and age in premenopausal women discriminates EOC and borderline tumors from benign tumors to higher accuracy compared to the Risk of Ovarian Malignancy Algorithm (p=0.007).,/p,,p,CONCLUSION: The biomarker panel suPAR(II-III), HE4, CA125 and age in ...
Abstract Objective To evaluate the value of individual and combined measurement of human epididymis protein 4 (HE4) and cancer antigen 125 (CA-125) in the diagnosis of ovarian cancer. Methods A clinical case-control study was performed in which the levels of serum HE4 and CA-125 of subjects with malignant, borderline, benign ovarian tumors and healthy women were measured before surgery. An immunohistochemistry method was used to measure the expression of HE4 in different tissues. Statistical analysis was performed to determine the relationship between the level of HE4 and the pathologic type as well as the stage of the ovarian tumors. Results The level of HE4 in the serum was significantly elevated in the malignant ovarian cancer group compared with other groups. Women with benign ovarian tumors and non-neoplastic lesions, and healthy women were designated as references. When the level of HE4 in the serum was 58.66 pmol/L, the sensitivity and specificity of HE4 in diagnosing malignant ovarian tumors
CA-7 is a job scheduling / workflow automation software package sold by CA Technologies (formerly CA, Inc. and Computer Associates International, Inc.).[1] It is commonly used by banks[2] and other large enterprises with IBM mainframe IT computing platforms. In 1987, Computer Associates took ownership of the product when it acquired its archrival, UCCEL Corporation. CA subsequently renamed it from UCC-7 to CA-7, as was done with product prefixes for UCC-1 (tape library management) and UCC-11 (batch job rerun/restart), etc. ...
Fatigue. Of course, most women may experience these symptoms from time to time. However, if any of these symptoms persist for longer than a few weeks, it may be an early sign of ovarian cancer and you should consult your doctor. Unfortunately, because the symptoms are so vague, many women dont see their doctor. As a result, they arent diagnosed until the cancer has spread beyond the ovaries into other areas of the body. If a doctor suspects ovarian cancer, he or she may try to determine a womans risk for ovarian cancer by taking a complete medical history. He or she may also ask about a family history of ovarian cancer or related cancers, age when menstruation started, number of pregnancies and use of birth control pills or fertility drugs.. If your doctor detects signs of ovarian cancer, he or she may perform a series of diagnostic tests. An ovarian cancer diagnosis can usually be made through a physical examination and a combination of diagnostic exams. Physical Examination ...
Ovarian cancer is the fourth most common cancer in women worldwide. It is very heterogeneous at the clinical, histopathological and molecular levels and is caused by the accumulation of genetic and epigenetic changes in regulatory genes. More than 90% of ovarian cancers are epithelial in origin. Ovarian cancer is typically asymptomatic in its early stages, and, due to difficulties in early detection, most ovarian cancers are diagnosed at an advanced stage. The positive predictive value of CA-125, a routinely used serum protein marker, is < 30%; therefore, for effective screening, there is a need to develop a marker with high sensitivity for early detection. Development of blood-based biomarkers that detect DNA methylation in cell-free tumor-specific DNA is now being considered as a potential approach for the early diagnosis of cancer. Our objective in this study was to develop an absolute quantitative method, the MethyLight assay, to detect the promoter methylation status of two tumor suppressor ...
The authour advocates that you should perform a yearly CA-125 ovarian cancer test, which should be even paid by your insurance (if you live in the USA, that is).. Maybe you should. Or you can ask a medical astrologer to see whether the period for cancer is really due.. ...
Gentaur molecular products has all kinds of products like :search , Prospecbio \ Mouse Anti Human Prostate Specific Cancer Antigen PSMA \ ant-450 for more molecular products just contact us
Pelvic masses are most commonly found in women, pelvic masses can also occur in men. Cases besides bladder distension and pregnancy need to be ruled out before workup. Consider every case as a malignancy. As age increases, so does the liklihood that malignancy could be a cause. ...
Researchers employing an extensive analysis of genomic information have identified micro RNA 506 (miR-506) as a potential therapeutic candidate for advanced or metastatic ovarian cancer situations. This high-risk cohort of ovarian cancer patients can be tested in mouse models of the disease to try and find better treatments.
Corsair Vengeance 2000 Wireless 7.1 Gaming Headset (CA-9011115-EU) at great prices. Full product description, technical specifications and customer reviews from BT Shop
Buy Thermaltake Core P5 ATX Open Frame Panoramic Viewing Gaming Computer Case No PSU - CA-1E7-00M1WN-00 with best customer reviews and fast shipping.
The mortality rate for ovarian cancer has remained roughly unchanged for the past 40 years. Various targeted therapies for ovarian cancer are under investigati...
Women with Ovarian cancer are different from Women without it because Women without it are not sick or potentially dying & are not fighting a potentially life threatening disease. Ovarian cancer is cancer of the Ovaries in a Woman.
Abstract: The 57Fe Mössbauer spectra of untreated, Ca- and K-saturated nontronite from Garfield, Washington, were measured. The spectrum of the untreated sample was computer-fitted to 8 peaks defining two octahedral, a tetrahedral, and an interlayer Fe3+-quadrupole-split doublets. In the Ca- and K-saturated samples interlayer Fe was absent. Spectra of the untreated sample were recorded at increasing increments of background counts from 2.8 × 105 to 9.2 × 106. An evaluation of the initial 4- and 6-peak models and the acceptable 8-peak model, computer-fitted to each spectrum, shows that if the X2 value is used as a measure of the goodness of the fit, the spectra should be recorded to a background count greater than 3 × 106. The resulting χ2 value then reflects both the validity of the model used and the extent of disorder within the structure. The χ2 value depends linearly on the background counts obtained.. A comparison of the spectra of the Ca- and K-saturated samples with that of the ...
My wife is 36 years of age. Operated for Malignant ovarian Cyst (CA-125 = 52) in October, 2006, recvd 6 cycles of carboplatin and Taxol, completed in February, 2007. In May, 2007 last CA-125 rose to ...
Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods o
Monoclonal clone# G2 antibody for CD8A; CD8B detection. Host: Mouse.Size: 100μg/vial. Tested applications: IHC-F. Reactive species: Human. CD8A; CD8B information: Molecular Weight: 23400 MW; Subcellular Localization: Membrane; Single-pass type I membrane
Monoclonal clone# G2 antibody for CD3/CD3E detection. Host: Mouse.Size: 100μg/vial. Tested applications: IHC-F. Reactive species: Human. CD3/CD3E information: Molecular Weight: 21312 MW; Subcellular Localization: CD3E: Membrane; Single-pass type I membra
Buy from Scan - ThermalTake Level 20 GT, Black, Full Tower Chassis with Window/s, ATX E-ATX MicroATX Mini-ITX, 1x140mm Fan,USB 3.0/2.0
There are different types of ovarian cancer - some are more common or less serious than others. Rare subtypes of ovarian cancer may be unique among other ovarian cancers. However, treatments are often the same. Read on to learn about these rare subtypes and how treatments work.
Whether youre worried about ovarian cancer, have been diagnosed or are a healthcare professional looking for more information, here you can find everything you need to know about ovarian cancer.
Whether youre worried about ovarian cancer, have been diagnosed or are a healthcare professional looking for more information, here you can find everything you need to know about ovarian cancer.
CA50, 0.5 mg. Cancer antigen 50 (CA50), a carcinoma associated carbohydrate antigen, has been found to be elevated in the blood of patients with colorectal cancer and other malignancies.
There are more than 30 different types of ovarian cancers. There are no early detection tests. Do you know symptoms of ovarian cancer?
At present there are no recommended routine screening tests for ovarian cancer. But there are many things a woman can do to help prevent ovarian cancer.
Missing a period can be a sign of something minor, or it could be ovarian cancer. Learn about the connection between a missed period and ovarian cancer.
A CA-125 blood test is used to detect a particular protein in the blood. While the test isnt accurate in all women, it is used to look for early cancers in certain high-risk patients and to monitor...
Ovarian cancer is highly curable if its diagnosed and treated early, but the symptoms can be easy to miss. Heres what to look for.
Care guide for Ovarian Cancer (Ambulatory Care). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Introduction: Ovarian cancer is one of the most common malignancies in women and the fifth cause of cancer-related deaths in women worldwide. Contrary to the challenges in developing new clinical markers using the conventional methods, recent advances in genomics and proteomics have led to identification of candidate and promising biomarkers for the diagnosis of ovarian cancer. Human epididymis protein 4 (HE4) is such a marker that has recently been reported to correlate with recurrence or progression of epithelial ovarian cancer. The purpose of this study was to measure the expression level of HE4 gene in women with ovarian cancer. Methodology: We evaluated and compared paraffin-embedded tissue samples of 20 ovarian cancer patients with 10 samples from healthy individuals. RNA was initially extracted from the samples and cDNA was synthetized. Gene expression level was then measured using real-time polymerase chain reaction (PCR). Results: Our results demonstrated that HE4 gene expression
Human Pancreatic Colorectal cancer (CA-242/CA242) ELISA Kit, 96 tests, Quantitative Kit 0060 Alpha Diagnostic International ADI San Antonio Texas Biotech Biotechnology monoclonal antibody Antibodies ELISA kits proteins and EIA reagent Human Pancreatic Colorectal cancer (CA-242) diagnostic patient serum plasma Human Pancreatic Colorectal cancer (CA-242/CA242) ELISA Kit, 96 tests, Quantitative Kit 0060 Alpha Diagnostic International ADI San Antonio Texas Biotech Biotechnology monoclonal antibody Antibodies ELISA kits proteins and EIA reagent Human Pancreatic Colorectal cancer (CA-242) diagnostic patient serum plasma
This is another one of our earlier cases of DCA. The patient was quite weak and advanced stage when DCA treatment was started. Based on our experience we felt that a moderate DCA dose with a 1 week on and 1 week off regimen could be effective and gentle enough for the patient to tolerate. If DCA was likely to work we might start to see some benefit and would prevent side effects by taking a week off.. This case illustrates a partial response of ovarian cancer to DCA treatment. Response was confirmed by a steady drop in the tumour marker CA-125 while the patient received DCA. The drop in CA-125 was consistent with the clinical improvement. DCA in the absence of other treatment resulted in significant quality of life improvement by relieving a bowel obstruction similar to our experience in other patients (including the Mesothelioma case report). Some of the blood tests worsened indicating incomplete control of the cancer.. This case also illustrates the DCA side effects of sedation and fatigue. ...
Benign ovarian tumours diagnosis (costs for program #147563) ✔ University Hospital of the Ludwig-Maximilians-University Munich ✔ Department of Gynecology, Obstetrics and Mammology ✔ BookingHealth.com
Benign ovarian tumours diagnosis (costs for program #143611) ✔ Academic Hospital Harlaching ✔ Department of Gynecology, Mammology and Obstetrics ✔ BookingHealth.com
TY - JOUR. T1 - Enhanced self-association of mucins possessing the T and Tn carbohydrate cancer antigens at the single-molecule level. AU - Haugstad, Kristin E.. AU - Gerken, Thomas A.. AU - Stokke, Bjørn T.. AU - Dam, Tarun K.. AU - Brewer, C. Fred. AU - Sletmoen, Marit. PY - 2012/5/14. Y1 - 2012/5/14. N2 - Mucins are linear O-glycosylated glycoproteins involved in inflammation, cell adhesion, and tumorigenesis. Cancer-associated mucins often possess increased expression of the T (Galβ1,3GalNAcαThr/Ser) and Tn (GalNAcαThr/Ser) cancer antigens, which are diagnostic markers for several cancers, including colon cancer. We have used AFM based single-molecule forced unbinding under near physiological conditions to investigate the self-interactions between porcine submaxillary mucin (PSM) as well as between PSM analogs possessing various carbohydrates including the T- and Tn-antigen. Distributions of unbinding forces and corresponding force loading rates were determined for force loading rates ...
Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. Easily share your publications and get them in front of Issuus millions of monthly readers. Title: 4 cancer antigen priorization frontiers 2012 gomez daniel, Author: P3DESIGN, Name: 4 cancer antigen priorization frontiers 2012 gomez daniel, Length: 2 pages, Page: 1, Published: 2013-08-05
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
In cases with findings on examination or imaging tests that suggest cancer, measuring blood levels of tumor markers may provide additional evidence for or against the diagnosis of cancer. Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. Tumor markers can be found in the blood, the urine, the tumor tissue, or other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is in the early stages. Some tumor marker levels can also be altered in patients with noncancerous conditions. In individuals who have been diagnosed with certain types of cancer, tumor markers may be useful to monitor the effectiveness of treatment and to detect possible recurrence of the cancer. For some cancers, the level of a ...
TY - JOUR. T1 - Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. AU - Andersen, John D.. AU - Boylan, Kristin L.M.. AU - Jemmerson, Ronald. AU - Geller, Melissa A.. AU - Misemer, Benjamin. AU - Harrington, Katherine M.. AU - Weivoda, Starchild. AU - Witthuhn, Bruce A.. AU - Argenta, Peter. AU - Vogel, Rachel Isaksson. AU - Skubitz, Amy P.N.. PY - 2010/10/14. Y1 - 2010/10/14. N2 - Background. New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection of disease recurrence. We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry. Methods. LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological ...
In several human malignancies, the expression of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is associated with aggressive characteristics and poor overall survival. RCAS1 alters the tumor microenvironment by inducing peripheral lymphocyte apoptosis and angiogenesis, while reducing the vimentin-positive cell population. Although proteolytic processing, referred to as “ectodomain shedding,” is pivotal for induction of apoptosis by RCAS1, the proteases involved in RCAS1-dependent shedding remain unclear. Here we investigated proteases involved in RCAS1 shedding and the association between tumor protease expression and serum RCAS1 concentration in uterine cancer patients. A disintegrin and metalloproteinase (ADAM) 9 was shown to be involved in the ectodomain shedding of RCAS1. Given the significant correlation between tumor ADAM9 expression and serum RCAS1 concentration in both cervical and endometrial cancer as well as the role for ADAM9 in RCAS1 shedding, further
The primary purpose of this work was to reproduce findings presented in Zhang et al. (2) in an independent study population. As in the previous report, differential analysis of protein profiles was conducted using serum samples collected postdiagnosis/pretreatment from ovarian cancer patients and women with benign ovarian tumors. When examined individually, levels of posttranslationally modified forms of transthyretin and apolipoprotein A1 were significantly lower in cancer cases compared with controls. In an ANOVA adjusted for age of patient and draw year, all biomarkers except apolipoprotein A1 were significantly different in cases than benign ovarian tumor or digestive disease controls. When these markers were combined into different prediction models, we found that the specificity of model 2, which included only the posttranslationally modified forms of transthyretin and apolipoprotein A1, was as high as model 3, which included age of patient, markers, and CA125 (96.5%; 95% CI, 91.9-98.8%), ...
Examples: Prostate-specific antigen, and CA-125 Tumor marker Calzone, Kathleen A. "Genetic Biomarkers of Cancer Risk". Seminars ... Bantis, A; Grammaticos, P (Sep-Dec 2012). "Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate ... CA-125 (Ovarian Cancer), CA19.9 (Pancreatic Cancer), CEA (Colorectal Cancer), EGFR (Non-small-cell lung carcinoma), HER-2 ( ... Breast Cancer), KIT (Gastrointestinal stromal tumor), PSA (Prostate Specific Antigen) (Prostate Cancer), S100 (Melanoma), and ...
Tumor markers including alphafetoprotein (AFP), Beta Human Chorionic Gonadotropin (HCG), Carcinoembionic Antigen (CEA), CA 125 ... Scholler, Nathalie; Urban, Nicole (2007-12-01). "CA125 in Ovarian Cancer". Biomarkers in medicine. 1 (4): 513-523. doi:10.2217/ ... ISBN 978-0-00-725092-9. Vickers, Andrew (1 March 2004). "Alternative Cancer Cures: "Unproven" or "Disproven"?". CA: A Cancer ... Prostate specific antigen (PSA). Treatment depends on the site and type of cancer. Breast cancer Treatment options include ...
Vickers, Andrew (1 March 2004). "Alternative Cancer Cures: "Unproven" or "Disproven"?". CA: A Cancer Journal for Clinicians. 54 ... Tumor markers including alphafetoprotein (AFP),[47] Beta Human Chorionic Gonadotropin (HCG),[47] Carcinoembionic Antigen (CEA), ... "CA125 in Ovarian Cancer". Biomarkers in Medicine. 1 (4): 513-523. doi:10.2217/17520363.1.4.513. ISSN 1752-0363. PMC 2872496 ...
There is no specific marker for immature teratomas, but carcinoembryonic antigen (CEA), CA-125, CA19-9, or AFP can sometimes ... CA-125 levels in premenopausal people over 200 U/mL may indicate ovarian cancer, as may any elevation in CA-125 above 35 U/mL ... CA-125 levels are not accurate in early stage ovarian cancer, as fully half of stage I ovarian cancer patients have a normal CA ... A blood test for a marker molecule called CA-125 is useful in differential diagnosis and in follow up of the disease, but it by ...
... is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly ... antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is ... Phase III of the trial showed no evidence of slowing ovarian cancer with a monoclonal antibody against CA125. "Medical News: ... Abagovomab does not bind directly to CA-125, but it works as a "surrogate" ...
CA 19-9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumour markers are found in primary liver ... Jemal, A; Bray, F; Center, MM; Ferlay, J; Ward, E; Forman, D (Mar-Apr 2011). "Global cancer statistics". CA: A Cancer Journal ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 ( ...
CA 19-9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumour markers are found in primary liver ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 ( ...
June 2008). "Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific ... Böttiger LE, Svedberg CA (1967). "Normal erythrocyte sedimentation rate and age". Br Med J. 2 (5544): 85-7. doi:10.1136/bmj. ... Carcinoembryonic Antigen(CEA) at MedicineNet Basuyau JP, Mallet E, Leroy M, Brunelle P (October 2004). "Reference intervals for ... R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. ...
... antigens, cd15 MeSH D23.050.285.050.115 --- ca-15-3 antigen MeSH D23.050.285.050.119 --- ca-19-9 antigen MeSH D23.050.285.050. ... antigens, cd15 MeSH D23.050.550.325.115 --- ca-15-3 antigen MeSH D23.050.550.325.119 --- ca-19-9 antigen MeSH D23.050.550.325. ... antigens, cd15 MeSH D23.101.840.075.115 --- ca-15-3 antigen MeSH D23.101.840.075.119 --- ca-19-9 antigen MeSH D23.101.840.075. ... hla-a antigens MeSH D23.050.301.500.450.370.372 --- hla-a1 antigen MeSH D23.050.301.500.450.370.374 --- hla-a2 antigen MeSH ...
CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic ... Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (Mar 2004). "Binding of ovarian cancer antigen CA125/ ... Yin BW, Dnistrian A, Lloyd KO (Apr 2002). "Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene". International ... Seelenmeyer C, Wegehingel S, Lechner J, Nickel W (Apr 2003). "The cancer antigen CA125 represents a novel counter receptor for ...
... also known as CA125, is an abbreviation for cancer antigen 125 125 High Street is a 30-floor highrise in Boston 125th ( ... California USNS Mission San Jose (T-AO-125), a US Navy fleet oiler during World War II USS Tide (AM-125), a US Navy minesweeper ... 125 is the cube of 5. It can be expressed as a sum of two squares in two different ways, 125 = 10² + 5² = 11² + 2². 125 and 126 ... Like many other powers of 5, it is a Friedman number in base 10 since 125 = 51 + 2. Air National Guard 125th Special Tactics ...
CA 19-9, CA 72-4 Liver: CEA, AFP Oesophagus: CEA, Cyfra 21-1 Thyroid: CEA, NSE Lung: CEA, CA 19-9, CA 125, NSE, Cyfra 21-1 ( ... Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (January 2008). "Value of cancer antigen 125 for ... CA 15-3, Cyfra 21-1 Ovary: CEA, CA 19-9, CA 125, AFP, BHCG Uterine: CEA, CA 19-9, CA 125, Cyfra 21-1, SCC Prostate: PSA, FPSA ... "Definition of CA 27-29. From MedicineNet. Last Editorial Review: 6/14/2012". gpnotebook.co.uk > ca-19-9 Retrieved November 2011 ...
Takayama TK, Carter CA, Deng T (2001). "Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human ... 276 (1): 125-33. doi:10.1006/bbrc.2000.3448. PMID 11006094. Gan L, Lee I, Smith R, et al. (2001). "Sequencing and expression ...
TAG-72 antigen entry in the public domain NCI Dictionary of Cancer Terms. Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J. ( ... tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 ... is a mouse monoclonal antibody that was designed for the treatment of cancers that express the TAG-72 antigen. This includes ... Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in ...
Cherwinski HM, Murphy CA, Joyce BL, et al. (2005). "The CD200 receptor is a novel and potent regulator of murine and human mast ... Dick AD, Broderick C, Forrester JV, Wright GJ (Jan 2001). "Distribution of OX2 antigen and OX2 receptor within retina". Invest ... 125 (6): x-xi. doi:10.1111/j.0022-202X.2005.23978.x. PMID 16354172. Shiratori I, Yamaguchi M, Suzukawa M, et al. (2005). "Down- ...
St Hill CA (2012). "Interactions between endothelial selectins and cancer cells regulate metastasis". Front. Biosci. 16: 3233- ... One of the reported ligands for E-selectin is the sialylated Lewis X antigen (SLex). Eosinophils, like neutrophils, use ... Bochner BS; Sterbinsky SA; Bickel CA; Werfel S; Wein M; Newman W (January 1994). "Differences between human eosinophils and ... Wein M; Sterbinsky SA; Bickel CA; Schleimer RP; Bochner BS (March 1995). "Comparison of human eosinophil and neutrophil ligands ...
... small clusters of microglial cells with enhanced major histocompatibility complex class II antigen, CD45 and CD68 antigen ... Rus H, Pardo CA, Hu L, et al. (August 2005). "The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory ... Haegele KF, Stueckle CA, Malin JP, Sindern E (February 2007). "Increase of CD8+ T-effector memory cells in peripheral blood of ... Given CA, Stevens BS, Lee C (1 January 2004). "The MRI appearance of tumefactive demyelinating lesions". AJR Am J Roentgenol. ...
Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin J, Lee SH, Lambert A, Zhao ZZ, Roseman F, Guo Q, Gordon SD, Wallace L, ... Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS (October 2016). "Diagnostic accuracy of cancer antigen 125 for ... The one biomarker that has been in use over the last 20 years is CA-125. A 2016 review found that in those with symptoms of ... CA-125 levels appear to fall during endometriosis treatment, but has not shown a correlation with disease response. Another ...
... histocompatibility antigen, class I, G, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is ... Gao GF, Willcox BE, Wyer JR, Boulter JM, O'Callaghan CA, Maenaka K, Stuart DI, Jones EY, Van Der Merwe PA, Bell JI, Jakobsen BK ... McIntire RH, Hunt JS (2005). "Antigen presenting cells and HLA-G--a review". Placenta. 26 Suppl A: S104-9. doi:10.1016/j. ... Moreau P, Dausset J, Carosella ED, Rouas-Freiss N (2003). "Viewpoint on the functionality of the human leukocyte antigen-G null ...
SRV-3 is present at Wisconsin Primate Center, while SRV-4 and SRV-5 have been identified at University of California and ... The SRV genome contains four genes: 5'-gag-prt-pol-env-3'. Gag encodes group-specific antigen, Prt for protease, Pol ... California and New England. The SRV serotype-2 was found in endemic infections of pig-tailed monkey (M. nemestrina), cynomolgus ... The extracellular mature particles are about 125 nm in diameter, while the nucleoid and core shell are central cylindrical ...
Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC (November 2001). " ... mediate CD4+ T cell killing of antigen-presenting macrophages". Journal of Immunology. 164 (6): 2897-904. doi:10.4049/jimmunol. ... 125 (Pt 19): 4475-86. doi:10.1242/jcs.099879. PMID 22767506. Wiley SR, Winkles JA (2004). "TWEAK, a member of the TNF ...
Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors ... "Prognosis and survival for acute lymphocytic leukemia - Canadian Cance". www.cancer.ca. Retrieved 2017-12-06. Nelson Essentials ... TdT is a protein expressed early in the development of pre-T and pre-B cells, whereas CALLA is an antigen found in 80% of ALL ... The process as a whole results in an effector cell, typically a T-cell, that can recognize a tumor cell antigen in a manner ...
Cui X, Hawari F, Alsaaty S, Lawrence M, Combs CA, Geng W, Rouhani FN, Miskinis D, Levine SJ (2002). "Identification of ARTS-1 ... affecting antigen presentation to cytotoxic T lymphocytes Aminopeptidases play a role in the metabolism of several peptides ... "The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues". Nature Immunology. 3 ... the name accepted by the Hugo Gene Nomenclature Committee ER aminopeptidase associated with antigen processing (ERAAP) ...
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). "Global cancer statistics". CA - A Cancer Journal for Clinicians ... Prostate specific membrane antigen is a transmembrane carboxypeptidase and exhibits folate hydrolase activity.[72] This protein ... Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005). "Cancer statistics, 2005". CA Cancer J ... Hellerstedt BA, Pienta KJ (2002). "The current state of hormonal therapy for prostate cancer". CA Cancer J Clin. 52 (3): 154-79 ...
"www.cancer.ca. Retrieved 2017-12-06.. *^ Nelson Essentials of Pediatrics By Karen Marcdante, Robert M. Kliegman, Richard E. ... Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors" ... TdT is a protein expressed early in the development of pre-T and pre-B cells, whereas CALLA is an antigen found in 80% of ALL ... Chimeric antigen receptors (CARs) have been developed as a promising immunotherapy for ALL. This technology uses a single chain ...
Journal of the California Dental Association. 41 (4): 263-8. PMID 23705242. Yamada T, Alpers DH, et al. (2009). Textbook of ... in persons with blood group O and in non-secretors of blood group antigens in saliva. Increased rates of Candida carriage are ... CA: A Cancer Journal for Clinicians. 62 (6): 400-22. doi:10.3322/caac.21157. PMID 22972543. Odell EW (Editor) (2010). Clinical ... 5 (2): 125-57. doi:10.1177/10454411940050020101. PMID 7858080. Li, X; Lei, L; Tan, D; Jiang, L; Zeng, X; Dan, H; Liao, G; Chen ...
Sometimes CA-125 may be ordered to help detect early ovarian cancer in women at high risk (e.g., BRCA mutation) or to help ... CA-125) is a tumor marker primarily used to monitor treatment of ovarian cancer and to detect whether cancer has come back ... If CA-125 levels rise or stay the same, then the cancer may not be responding to therapy. High CA-125 levels after treatment is ... CA-125 is also used to detect whether cancer has come back after treatment is complete. A series of CA-125 tests that shows ...
The CA-125 blood test can spot proteins made by ovarian cancer, but it doesnt always mean you have cancer. WebMD explains why ... The CA-125 test also may be done if you have a lump in your pelvic area. It will help your doctor figure out the cause of the ... Cancer antigen 125 test Your doctor may order a CA-125 test if youre about to start treatment for ovarian cancer. The test ... The CA-125 test looks for certain proteins in your blood. Ovarian cancer can be the reason for these proteins, but other ...
CA125) is a protein produced by a variety of cells, particularly ovarian cancer cells. It is found in trace amounts in the ... How a CA125 test is done. A CA125 test is a blood test that measures the amount of CA125 protein in the blood. A sample of ... Why a CA125 test is done. A CA125 test may be done: * if the doctor suspects there may be cancer ... CA125). Cancer antigen 125 (CA125) is a protein found on most ovarian cancer cells that is secreted into the blood stream and ...
Read our Cancer Antigen 125 (CA-125) encyclopedia resources online. ... CA-125) test that can help show if some types of cancer are present. Covers its use to check how well treatment for ovarian ... Cancer Antigen 125 (CA-125). Skip to the navigation Test Overview. Cancer antigen 125 (CA-125) is a protein found on the ... CA-125 is used as a tumor marker, which means the test can help show if some types of cancer are present. Most often, the CA- ...
CA-125) test that can help show if some types of cancer are present. Covers its use to check how well treatment for ovarian ... Cancer antigen 125 (CA-125) is a protein found on the surface of many ovarian cancer cells. It also can be found in other ... CA-125 is used as a tumor marker, which means the test can help show if some types of cancer are present. Most often, the CA- ... High values of CA-125 in a woman who has been treated for ovarian cancer may mean that the cancer has returned. Often the high ...
CA-125) tumor marker for Ovarian and other malignant cancers for research and in vitro diagnostic manufacturing - Inquire for ... Home / Antigens / Enzymes / Antigens / Standards / Controls / Proteins / Cancer Antigen 125 (ca-125) ... CA125) is a surface antigen associated with epithelial ovarian cancer. In serum, CA125 is associated with a high molecular ... Low Cross Contamination: CA 15-3, CEA, CA 19-9. Formulation. Solution in phosphate buffered saline pH 7.4 with 3% sucrose and ...
CA-125) monoclonal antibody for research, life science and manufacturing uses - Inquire for more details! ... Antigens , Enzymes. We produce and manufacture high quality antigens, proteins and enzymes for a wide range of life science ... Capture Ab: 151-29 - anti-Human CA-125 Monoclonal Antibody. Detection Ab: 151-30 - anti-Human CA-125 Monoclonal Antibody. ...
Colorimetric Assay for Quantitative measurement of human CA-125 in serum, plasma, urine & cell culture supernatants. Detection ... Milpitas, CA 95035.. Tel: 408.493.1800. Fax: 408.493.1801. Toll Free: 800.891.9699 (US Only). Tech Support: [email protected]. ... CA-125 Ab-coated Microplate, 96 wells. • Wash Buffer (20x). • Human CA-125 Standard. • Assay Diluent (5x). • Detection Antibody ... The minimum detectable dose of CA-125 is typically less than 0.6 U/ml. Detection Range: 0.6 U/ml - 400 U/ml. The intra-Assay ...
... cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in ... CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease. Mikkelsen, Gustav; Åsberg, Arne; Hultström, Maria ... Estimated reference limits for plasma CA 125, CA 19-9 and CEA were approximately the same as for healthy populations. Serum ... Reference limits for chromogranin A, CYFRA 21-1, CA 125, ...
Mouse Carbohydrate Antigen 125 (CA125) ELISA Kit-P06731.3 (MBS264824) product datasheet at MyBioSource, ELISA Kits ... carcinoembryonic antigen-related cell adhesion molecule 5; meconium antigen 100 UniProt Protein Name Carcinoembryonic antigen- ... The ELISA analytical biochemical technique of the MBS264824 kit is based on CA125 antibody-CA125 antigen interactions ( ... CA125 elisa kit :: Mouse Carbohydrate Antigen 125 (CA125) ELISA Kit. Catalog #. MBS264824 .mycenter { display: block; margin- ...
Bovine Ovarian Cancer Marker/Carbohydrate Antigen 125 ELISA Kit (MBS023627) product datasheet at MyBioSource, ELISA Kits ... The ELISA analytical biochemical technique of the MBS023627 kit is based on OCM-CA125 antibody-OCM-CA125 antigen interactions ( ... OCM-CA125 Bovine OCM-CA125. LOG IN MY ACCOUNT CART CONTENTS CHECKOUT ... OCM-CA125 elisa kit :: Bovine Ovarian Cancer Marker/Carbohydrate Antigen 125 ELISA Kit. ...
Mouse Ovarian cancer marker/Carbohydrate antigen 125 ELISA Kit (MBS720972) product datasheet at MyBioSource, ELISA Kits ... The intensity of the color is inversely proportional to the CA125 concentration since CA125 from samples and CA125-HRP ... Ovarian cancer marker-CA125 Mouse Ovarian cancer marker-CA125. LOG IN MY ACCOUNT CART CONTENTS CHECKOUT ... CA125 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-CA125 antibody and an CA125- ...
Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and ... Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and ... Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and ... The specificity of CA 125 at upper limits of 30 and 50 U/mL was increased from 97.0 and 99.5%, respectively, to 98.9 and 99.9% ...
CA 125 Antigen. CA 125 Antigen is a heterogonous glycoprotein. It can be detected in ovarian cancer. Moderately elevated values ... CA 125 determination is used mainly for diagnosis and monitoring of ovarian cancer. ...
There are two common oncofetal antigens, alphafetoprotein (AFP) and carcinoembryonic antigen (CEA). Carcinoembryonic antigen CA ... Some widely used tumor markers include: AFP, beta-HCG, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, and PSA. Some tumor markers are ... Some widely used tumor markers include: AFP, beta-HCG, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, and PSA. Some tumor markers are ... Cancer antigen 15-3 (CA 15-3) CA 15-3 is produced by cells in the breast and increased levels can be associated with breast ...
TEST : Access Ovarian Cancer Test - OV Monitor (CA 125 antigen) Access OV Monitor aids in the management of ovarian cancer and ... CA 125 antigen levels are most consistently elevated in patients with ovarian cancer. The assay produces first results in 20 ... ACCESS Tumor marker - OV monitor (CA 125 Antigen). BECKMAN - Tumor marker TEST Access Ovarian Cancer Test - OV Monitor CA 125 ... such as transvaginal ultrasonography and a mathematical algorithm that analyzes rates of change of CA 125. The test is ...
CA125 Enzyme Immunoassay. INTENDED USE. For the quantitative determination of the Cancer Antigen CA125 concentration in human ... CA125) is a surface antigen associated with epithelial ovarian cancer. In serum, CA125 is associated with a high molecular ... Enzyme Immunoassay for the Quantitative Determination of Ovarian Cancer Antigen CA125 in Human Serum. FOR IN VITRO DIAGNOSTIC ... CA125 is an antigen present on 80 percent of nonmucinous ovarian carcinomas. It is defined by a monoclonal antibody ( OC125 ) ...
CA 27.29 - Cancer Antigen. 140293 - Quantitative measurement of Cancer Antigen 27.29. This testing is often done to help manage ... Carbohydrate Antigen 19-9 (CA 19-9). 002261 - The CA 19-9 is used to monitor gastrointestinal, pancreatic, liver and colorectal ... Cancer Antigen (CA) 15-3. 143404 - Quantitative measurement of cancer antigen 15-3. ... Cancer Antigen (CA) 125. 002303 - A CA 125 test measures the amount of the protein CA 125 (cancer antigen 125) in your blood. A ...
CA125) and cancer antigen 15.3 (CA15.3). The results for CA125 in this data release are reported as U/mL. The results for ... Cancer antigen CA125 and CA15.3 - Serum (SSCA_B). Data File: SSCA_B.xpt. First Published: June 2019. Last Revised: NA. ... Cancer antigen 15.3 (mU/mL). English Text: Cancer antigen 15.3 (mU/mL). Target: Females only 20 YEARS - 150 YEARS. Code or ... Human CA125 (single spot, catalog number K151WC) The linearity range for the CA125 was 10,000-0.6 U/ml (low limit of detection ...
James Lanier is treating Asbestosis, Laryngeal Cancer, Lung Cancer, Ovarian Cancer, Pericardial Mesothelioma , Peritoneal Mesothelioma, Pleural Effusions, Pleural Mesothelioma, Pleural Plaques, Pleuritis, Testicular Mesothelioma To request an appointment with James Lanier call us at (435) 200-5326.
Barbara Herfel is treating Asbestosis, Clubbed Fingers, Diffuse Pleural Thickening, Laryngeal Cancer, Lung Cancer, Ovarian Cancer, Pericardial Mesothelioma , Pericardial Mesothelioma , Pleural Mesothelioma, Pleuritis, Rounded Atelectasis, Testicular Mesothelioma To request an appointment with Barbara Herfel call us at (435) 200-5326.
To get results back for an STD test that requires laboratory testing usually takes about a week, according to Rutgers Medical Services. Not all tests for STDs require laboratory testing, however, and...
What Is Considered Positive for a CA-125 Cancer Antigen Test?. * Q: What Is Social Anxiety?. ...
Melanomas present on the skin with brownish spots, irregular lesions or moles that change color and size, according to the Mayo Clinic. Melanomas are the most dangerous form of skin cancer, and the...
  • Include markers defined by both monoclonal antibodies and polyclonal antisera, often the so called oncofetal antigens. (thailabonline.com)
  • The test sample is allowed to react simultaneously with the two antibodies, resulting in the CA125 molecules being sandwiched between the solid phase and enzyme-linked antibodies. (thailabonline.com)
  • These tests typically identify "antigens," or abnormal substances in the blood that cause the immune system to produce antibodies against it. (healthcheckusa.com)
  • When the biofluid sample was passed on the CA-125 antibodies that are immobilized on the gold interdigitated electrodes, the capacitance variation of the sensing circuit was caused due to the antigen - antibody interaction. (lee-research.org)
  • However, the capacitance measured during CA-125 antigen - antibody interaction with the microfluidic flow condition (270.34 pF) was lower than static drop condition (296.09 pF) due to the instability of the immobilized antibodies on the sensing surface that was caused by the shear stress on the sensing surface during the microfluidic flow. (lee-research.org)
  • The CA-125 test looks for certain proteins in your blood . (webmd.com)
  • ARTS1 is also known as: ER aminopeptidase 1 (ERAP1) the name accepted by the Hugo Gene Nomenclature Committee ER aminopeptidase associated with antigen processing (ERAAP) Adipocyte-derived leucine aminopeptidase (ALAP) Puromycin-insensitive leucine aminopeptidase (PILS-AP) ERAP1 has two major functions in the immune system: First, ERAP1 cleaves several proteins called cytokine receptors on the surface of cells. (wikipedia.org)
  • MUC16 (CA-125) has been shown to play a role in advancing tumorigenesis and tumor proliferation by several different mechanisms. (wikipedia.org)
  • Tumor markers including alphafetoprotein (AFP), Beta Human Chorionic Gonadotropin (HCG), Carcinoembionic Antigen (CEA), CA 125, Prostate specific antigen (PSA). (wikipedia.org)
  • Screening for specific cancer types or locations requires a level of specificity and sensitivity that has so far only been reached by Example: elevated prostate specific antigen suggests that is used in some countries to screen for prostate cancer. (wikipedia.org)
  • Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene. (wikipedia.org)
  • A review commissioned by the U.S. Preventive Services Task Force concluded that "Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary," or more simply, "[t]he potential benefit does not outweigh the expected harms" in patients not already diagnosed or being treated for prostate cancer. (wikipedia.org)
  • Dr. Edwin Monuki graduated from the University of California San Diego School of Medicine and completed his residency program at the Massachusetts General Hospital. (mesotheliomadr.com)
  • Dr. Alicia Bhambra graduated from the Touro University California College of Osteopathic Medicine and completed her residency program at the University of California Irvine. (mesotheliomadr.com)
  • She completed her residency in Anatomic and Clinical Pathology at the University of California, San Diego and also did a fellowship in Cytopathology at the UCSF. (mesotheliomadr.com)
  • He got his diploma from University of Hong Kong Faculty of Medicine and did his residency program in Anatomic and Clinical Pathology at the University of Southern California - LAC+USC Medical Center. (mesotheliomadr.com)
  • Dr. Christie Pang graduated from the Boston University School of Medicine and completed her residency program at the University of Southern California. (mesotheliomadr.com)
  • Dr. Haydel completed her medical education with a residency in anatomic and clinical pathology at the University of California Irvine in 2012, a fellowship in pediatric pathology at the Children's Hospital of Los Angeles in 2013 and a fellowship in dermatopathology at the University of California Los Angeles in 2015. (mesotheliomadr.com)
  • He got his diploma from Nova Southeastern University College of Osteopathic Medicine and did his residency years in Anatomic and Clinical Pathology at the University of California Irvine. (mesotheliomadr.com)
  • She got her diploma from Loma Linda University School of Medicine and did her residency program in Anatomic and Clinical Pathology at the University of Southern California - LAC+USC Medical Center and Loma Linda University. (mesotheliomadr.com)
  • Dr. Julia Chu graduated from the Harvard Medical School and completed her residency program at the University of California Irvine. (mesotheliomadr.com)
  • Dr. Abrahams completed her medical education with a residency in anatomic and clinical pathology at Loma Linda University, a residency in anatomic and clinical pathology at the University of Southern California - LAC+USC Medical Center and a fellowship in surgical pathology in the Department of Pathology at Los Angeles County-USC Medical Center. (mesotheliomadr.com)
  • Dr. Moises Zepeda graduated from the Keck School of Medicine of USC and completed both his residency and fellowship program at the University of Southern California. (mesotheliomadr.com)
  • She completed a residency at the University of California San Diego and a fellowship at the University of California San Diego. (mesotheliomadr.com)
  • The understanding of cytotoxic T-lymphocyte antigen-4 (CTLA-4) which lead to the development of Ipi shows again that Gulley and his team have a considerable grasp of what can work in the human cancer vaccine arena. (wikipedia.org)
  • 002261 - The CA 19-9 is used to monitor gastrointestinal, pancreatic, liver and colorectal malignancies. (mcssl.com)
  • NCBI/Uniprot data below describe general gene information for CA125 . (mybiosource.com)
  • HLA-G histocompatibility antigen, class I, G, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is encoded by the HLA-G gene. (wikipedia.org)
  • Entrez Gene: HLA-G HLA-G histocompatibility antigen, class I, G". Castelli, Erick C. (wikipedia.org)
  • CD200 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Human CD200 genome location and CD200 gene details page in the UCSC Genome Browser. (wikipedia.org)
  • NF-κB is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. (wikipedia.org)
  • Dr. Wilson Chick is a pathology specialist offering his services in Loma Linda, California and he works at several hospitals in the area, such as Foothill Presbyterian Hospital and Garfield Medical Center. (mesotheliomadr.com)
  • Dr. Antony Chen is a pathology doctor in Garden Grove, California and he works at New York Hospital Queens. (mesotheliomadr.com)
  • Dr. Evelyn Choo is a pathology specialist in Loma Linda, California and she works at several hospitals in the area, such as Loma Linda University Medical Center and Veterans Affairs Loma Linda Healthcare System. (mesotheliomadr.com)
  • Dr. Shulan Tian is a pathology medical specialist in Glendale, California and she works at several hospitals in the area, such as Glendale Adventist Medical Center and Simi Valley Hospital and Health Care Services. (mesotheliomadr.com)
  • If a doctor has found a cancer that has spread to another part of the body (metastatic cancer), he or she may do a CA-125 test to find out where the cancer started. (northshore.org)
  • A very high level of CA-125 is something the doctor will want to look into, but it doesn't always mean you have ovarian cancer. (webmd.com)
  • A decrease in the CA125 level during treatment usually means that the cancer is responding to treatment. (cancer.ca)
  • If the CA125 level stays the same or rises during treatment, it may mean that the cancer is not responding to treatment. (cancer.ca)
  • A high CA125 level after treatment is complete may mean that the cancer has come back (recurred). (cancer.ca)
  • If the level of CA-125 is going down, it usually means that the treatment is working. (northshore.org)
  • Often the high CA-125 level is found many months before the return of cancer can be found in another way. (northshore.org)
  • CA125 is often elevated in patients with ovarian cancer, its level following the patient's clinical course. (thailabonline.com)
  • Women who continued their first trimester of pregnancy showed a significantly higher number of previous abortions and progesterone level (43.12±20.85 vs. 19.26±11.8, P = 0.01) and lower level of CA 125 (34.9±11.053 vs. 61.9±19.21, P = 0.022) when compared with those who aborted. (ekb.eg)
  • Indeed, a rising CA-125 level may precede clinical evidence of disease relapse by an interval of 3 to 6 months. (wikipedia.org)